Search

Author/Creator Padula, Steven J.

1. Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects. Issue 4 (9th December 2020)

Authors:
Tsuda, Yasuhiro; Grimaldi, Christine; Huang, Fenglei; Benediktus, Ewald; Yagi, Nobutaka; Padula, Steven J.; Jang, In‐Jin; Steffgen, Jürgen
Journal:
British journal of clinical pharmacology
Issue:
Volume 87:Issue 4(2021)
Page Start:
2000
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Safety, pharmacokinetics and pharmacodynamics of BI 705564, a highly selective, covalent inhibitor of Bruton's tyrosine kinase, in Phase I clinical trials in healthy volunteers. Issue 4 (20th November 2020)

Authors:
Litzenburger, Tobias; Steffgen, Jürgen; Benediktus, Ewald; Müller, Fabian; Schultz, Armin; Klein, Elliott; Ramanujam, Meera; Harcken, Christian; Gupta, Alpana; Wu, Jing; Wiebe, Sabrina; Li, Xiujiang; Flack, Mary; Padula, Steven J.; Visvanathan, Sudha; Hünnemeyer, Andreas; Hui, Jianan
Journal:
British journal of clinical pharmacology
Issue:
Volume 87:Issue 4(2021)
Page Start:
1824
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti‐CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases. (16th August 2018)

Authors:
Schwabe, Christian; Rosenstock, Bernd; Doan, Thi; Hamilton, Paul; Dunbar, P. Rod; Eleftheraki, Anastasia G.; Joseph, David; Hilbert, James; Schoelch, Corinna; Padula, Steven J.; Steffgen, Jürgen
Journal:
Journal of clinical pharmacology
Issue:
Volume 58:Number 12(2018)
Page Start:
1566
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗